Back to top
more

GSK PLC Sponsored ADR (GSK)

(Real Time Quote from BATS)

$41.11 USD

41.11
1,352,083

-0.07 (-0.17%)

Updated Aug 14, 2024 02:25 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Company News for Jun 24, 2021

by Zacks Equity Research

Companies in The News Are: PDCO,GSK,SHAK,SON

Kinjel Shah headshot

Pharma Stock Roundup: EU Nod to AZN, SNY, JNJ Drugs, Glaxo's New COVID-19 Drug Data

by Kinjel Shah

EU approves AstraZeneca's (AZN) rare disease drug, Koselugo and expanded use of J&J's (JNJ) Darzalex Faspro and Sanofi's (SNY) Aubagio.

Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine

by Zacks Equity Research

Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.

    Halozyme (HALO) Inks Collaboration Deal With Glaxo's HIV Unit

    by Zacks Equity Research

    Halozyme (HALO) and Glaxo's HIV company, ViiV Healthcare sign a collaboration agreement, which gives the latter exclusive right to Halozyme's ENHANZE technology to develop therapies targeting HIV

    The Zacks Analyst Blog Highlights: Exxon Mobil, Texas Instruments, GlaxoSmithKline, Norfolk Southern and Corning

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Exxon Mobil, Texas Instruments, GlaxoSmithKline, Norfolk Southern and Corning

    Mark Vickery headshot

    Top Stock Reports for Exxon Mobil, Texas Instruments & GlaxoSmithKline

    by Mark Vickery

    Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), Texas Instruments (TXN), and GlaxoSmithKline (GSK).

    Theravance (TBPH) COVID-19 Therapy Fails in Mid-Stage Study

    by Zacks Equity Research

    Theravance's (TBPH) JAK inhibitor candidate, nezulcitinib, fails to achieve statistically significant improvement in the number of respiratory failure-free days in hospitalized COVID-19 patients with lung injury.

    Glaxo (GSK)/Vir Affirm COVID-19 Drug Cuts Hospitalization/Death

    by Zacks Equity Research

    Glaxo (GSK)/Vir Biotech's new data confirms that COVID-19 treatment, sotrovimab can cut hospitalization and risk of death. ViiV Healthcare inks deal with Halozyme to use its ENHANZE technology to make better HIV medicines.

    Gilead (GILD) Veklury Data Positive in Hospitalized COVID Patients

    by Zacks Equity Research

    Gilead (GILD) announces positive data on Veklury in hospitalized patients with COVID-19 across three analyses of large retrospective real-world data sets.

    Kinjel Shah headshot

    Pharma Stock Roundup: AZN COVID-19 Antibody Cocktail Failure, GSK New Cancer Deal

    by Kinjel Shah

    AstraZeneca's (AZN) phase III study on COVID-19 antibody cocktail fails to meet primary goal. Glaxo (GSK) signs a new co-development/commercialization deal for a cancer candidate with iTeos Therapeutics.

    CureVac (CVAC) Plummets on Disappointing COVID-19 Vaccine Data

    by Zacks Equity Research

    CureVac (CVAC) down as it announces that its first-generation COVID-19 vaccine candidate, CVnCoV, did not meet the prespecified statistical success criteria in a phase IIb/III study.

    Biotech Stock Roundup: SAGE Declines on Data, Regulatory Updates From VRTX, ITOS

    by Zacks Equity Research

    The biotech sector was in focus last week with regulatory updates from Sage (SAGE) and Vertex (VRTX), among others.

    Regeneron (REGN) Announces Data on COVID-19 Antibody Cocktail

    by Zacks Equity Research

    Regeneron (REGN) announces positive results from a phase III study on antibody cocktail, REGEN-COV.

    AstraZeneca (AZN) Antibody Cocktail Fails to Prevent COVID-19

    by Zacks Equity Research

    AstraZeneca's (AZN) antibody cocktail, AZD7442 fails to prevent people who were already infected from developing symptomatic COVID-19. However, it showed some efficacy in people who were not infected.

    Glaxo (GSK)/iTeos Therapeutics to Co-Develop Novel Cancer Drug

    by Zacks Equity Research

    Glaxo (GSK) signs deal with iTeos Therapeutics to co-develop its investigational cancer candidate known as EOS-448. Glaxo will also study EOS-448 with its other investigational cancer therapies.

    Gilead (GILD) Gets FDA Nod for Label Expansion of Epclusa

    by Zacks Equity Research

    Gilead (GILD) obtains FDA approval for the label expansion of HCV drug, Epclusa, to include children as well.

    VBI Vaccines (VBIV) Up on Glioblastoma Drug Fast Track Status

    by Zacks Equity Research

    VBI Vaccines (VBIV) is developing VBI-1901 as a potential treatment of recurrent glioblastoma patients.

    Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug

    by Zacks Equity Research

    Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.

    CureVac (CVAC) Announces Positive Data on COVID-19 Vaccine

    by Zacks Equity Research

    CureVac (CVAC) announces the continuation of its COVID-19 vaccine study following the first interim analysis in 59 eligible COVID-19 cases.

    Kinjel Shah headshot

    Pharma Stock Roundup: JNJ Cancer Drug Gets FDA Nod, PFE, GSK, SNY Begin New Studies

    by Kinjel Shah

    Sanofi (SNY) and Glaxo's (GSK) COVID-19 vaccine candidate enters phase III. FDA approves J&J's (JNJ) Rybrevant (amivantamab) for a rare lung cancer

    Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study

    by Zacks Equity Research

    Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.

    Vir Biotech (VIR)/Glaxo COVID-19 Drug Gets FDA Emergency Nod

    by Zacks Equity Research

    Glaxo (GSK)/VIR Biotech's (VIR) sotrovimab demonstrated an 85% reduction in hospitalization or death in a study evaluating it in high-risk COVID-19 patients.

    Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer

    by Zacks Equity Research

    The CHMP recommends approval of Merck's (MRK) anti-PD-1 therapy, Keytruda in combination with chemotherapy for the first-line treatment of esophageal and gastroesophageal junction carcinoma in Europe.

    Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod

    by Zacks Equity Research

    The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.

    The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck

    by Zacks Equity Research

    The Zacks Analyst Blog Highlights: Sanofi, GlaxoSmithKline, Pfizer, Eli Lilly and Merck